E2F-7 Inhibitors
E2F-7 is a member of the E2F family of transcription factors, which play critical roles in the regulation of cell cycle progression, DNA replication, and apoptosis. Unlike other E2F family members that promote cell cycle progression, E2F-7 functions primarily as a negative regulator of cell cycle progression and cell proliferation. It acts by repressing the transcription of genes involved in cell cycle progression, including those encoding cyclins, cyclin-dependent kinases (CDKs), and DNA replication factors. E2F-7 exerts its inhibitory effects by binding to specific DNA sequences known as E2F-binding sites and recruiting transcriptional corepressors, such as retinoblastoma protein (RB) and histone deacetylases (HDACs), to suppress gene expression. Additionally, E2F-7 has been implicated in regulating DNA damage responses and promoting cell cycle arrest and apoptosis in response to genotoxic stress, further emphasizing its role as a negative regulator of cell proliferation.
Inhibition of E2F-7 activity can be achieved through various mechanisms that disrupt its DNA binding, transcriptional activity, or protein-protein interactions. One approach to inhibiting E2F-7 function is through the use of small molecules or peptides that target its DNA-binding domain, preventing its association with E2F-binding sites in the promoter regions of target genes. Additionally, compounds that interfere with the recruitment of transcriptional corepressors or enhance the activity of transcriptional coactivators can disrupt the repressive function of E2F-7, leading to the derepression of target genes involved in cell cycle progression. Furthermore, modulation of upstream signaling pathways that regulate E2F-7 expression or activity, such as the p53 pathway or the RB pathway, represents another potential strategy for inhibiting E2F-7 function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib, similar to Palbociclib, inhibits CDK4 and CDK6, directly impacting the Rb-E2F pathway. Inhibition of these kinases results in decreased activation of E2F-7, disrupting its transcriptional activity and hindering cellular processes associated with cell cycle progression and proliferation. | ||||||
N-[5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine Methanesulfonate | 1231930-82-7 | sc-496536 | 2.5 mg | $398.00 | ||
Abemaciclib, another CDK4 and CDK6 inhibitor, directly influences the Rb-E2F pathway, leading to decreased activation of E2F-7. This direct inhibition disrupts E2F-7's transcriptional activity, affecting cellular processes related to cell cycle regulation and proliferation. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
PD-0332991 inhibits CDK4 and CDK6, directly impacting the Rb-E2F pathway. Inhibition of these kinases leads to reduced activation of E2F-7, disrupting its transcriptional activity and hindering cellular processes associated with cell cycle progression and proliferation. | ||||||
RO-3306 | 872573-93-8 | sc-358700 sc-358700A sc-358700B | 1 mg 5 mg 25 mg | $66.00 $163.00 $326.00 | 37 | |
RO-3306 is a selective CDK1 inhibitor, directly impacting the cell cycle machinery. Inhibition of CDK1 influences the Rb-E2F pathway, leading to decreased activation of E2F-7. This direct inhibition disrupts E2F-7's transcriptional activity, affecting cellular processes related to cell cycle progression and proliferation. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
AZD5438 is a CDK1/2/9 inhibitor, directly influencing the cell cycle. Inhibition of CDK1 and CDK2 by AZD5438 impacts the Rb-E2F pathway, leading to reduced activation of E2F-7. This direct inhibition disrupts E2F-7's transcriptional activity, affecting cellular processes related to cell cycle regulation and proliferation. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib inhibits CDK1, CDK2, CDK5, and CDK9, directly impacting the cell cycle machinery. Inhibition of these CDKs influences the Rb-E2F pathway, leading to decreased activation of E2F-7. This direct inhibition disrupts E2F-7's transcriptional activity, affecting cellular processes related to cell cycle progression and proliferation. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol is a broad-spectrum CDK inhibitor, directly influencing the cell cycle. Inhibition of various CDKs by Flavopiridol impacts the Rb-E2F pathway, leading to reduced activation of E2F-7. This direct inhibition disrupts E2F-7's transcriptional activity, affecting cellular processes related to cell cycle regulation and proliferation. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine (Seliciclib) inhibits CDK2, CDK7, and CDK9, directly impacting the cell cycle machinery. Inhibition of these CDKs influences the Rb-E2F pathway, leading to decreased activation of E2F-7. This direct inhibition disrupts E2F-7's transcriptional activity, affecting cellular processes related to cell cycle progression and proliferation. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Purvalanol A is a CDK inhibitor targeting CDK1, CDK2, CDK5, and CDK7, directly influencing the cell cycle. Inhibition of these CDKs by Purvalanol A impacts the Rb-E2F pathway, leading to reduced activation of E2F-7. This direct inhibition disrupts E2F-7's transcriptional activity, affecting cellular processes related to cell cycle regulation and proliferation. | ||||||
R547 | 741713-40-6 | sc-364596 sc-364596A | 2 mg 5 mg | $375.00 $395.00 | ||
R547 is a selective CDK inhibitor targeting CDK1, CDK2, and CDK4, directly impacting the cell cycle machinery. Inhibition of these CDKs influences the Rb-E2F pathway, leading to decreased activation of E2F-7. This direct inhibition disrupts E2F-7's transcriptional activity, affecting cellular processes related to cell cycle progression and proliferation. | ||||||